Literature DB >> 12453719

Patient characteristics determine differences in the influenza vaccination rate more so than practice features.

Margot Tacken1, Jozé Braspenning, Peter Spreeuwenberg, Henk van den Hoogen, Gerrit van Essen, Dinny de Bakker, Richard Grol.   

Abstract

BACKGROUND: World-wide each year 30-55% of the target population is vaccinated against influenza. Determinants of successful vaccination programs are not clear. This study was aimed at identifying practice- and patient-related factors that determine differences in vaccination rates.
METHODS: Data on patients of the target population were extracted from the computerized medical record systems of 48 family practices. Information about organizational factors was collected by a questionnaire for GP's. Multilevel logistic regression analyses were used to assess the determinants.
RESULTS: Of all patients at risk (42,426), 76% were vaccinated. The vaccination rate for patients above age 65 was 15% higher when a medical indication was present. Patients with cardiac diseases or diabetes mellitus attained a relatively higher vaccination rate than other groups at risk. Special hours for vaccination led to significantly higher vaccination rates for the elderly and cardiac patients. Patients below 65 years of age were particularly influenced by special information pamphlets.
CONCLUSION: Explanations of differences in uptake rates were found at the patient level. All practices in this study were well organized; nevertheless, subgroup analyses showed that special vaccination hours for elderly people and information pamphlets for young people could improve results further. Copyright 2002 American Health Foundation and Elsevier Science (USA)

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12453719     DOI: 10.1006/pmed.2002.1083

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  8 in total

1.  Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK.

Authors:  Beate Sander; Frederick G Hayden; Marlene Gyldmark; Louis P Garrison
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  Predictors of influenza immunization among home care clients in Ontario.

Authors:  John P Hirdes; Dawn M Dalby; R Knight Steel; G Iain Carpenter; Roberto Bernabei; John N Morris; Brant E Fries
Journal:  Can J Public Health       Date:  2006 Jul-Aug

3.  Perceived vaccination status in ecotourists and risks of anthropozoonoses.

Authors:  Michael P Muehlenbein; Leigh Ann Martinez; Andrea A Lemke; Laurentius Ambu; Senthilvel Nathan; Sylvia Alsisto; Patrick Andau; Rosman Sakong
Journal:  Ecohealth       Date:  2008-09-23       Impact factor: 3.184

Review 4.  Interventions to increase influenza vaccination rates of those 60 years and older in the community.

Authors:  Roger E Thomas; Diane L Lorenzetti
Journal:  Cochrane Database Syst Rev       Date:  2014-07-07

Review 5.  Interventions to increase influenza vaccination rates of those 60 years and older in the community.

Authors:  Roger E Thomas; Diane L Lorenzetti
Journal:  Cochrane Database Syst Rev       Date:  2018-05-30

6.  Variations in influenza vaccination coverage among the high-risk population in Sweden in 2003/4 and 2004/5: a population survey.

Authors:  Madelon W Kroneman; Gerrit A van Essen
Journal:  BMC Public Health       Date:  2007-06-14       Impact factor: 3.295

7.  Prescription of antiviral drugs during the 2009 influenza pandemic: an observational study using electronic medical files of general practitioners in the Netherlands.

Authors:  Mariëtte Hooiveld; Tine van de Groep; Theo J M Verheij; Marianne A B van der Sande; Robert A Verheij; Margot A J B Tacken; Gerrit A van Essen
Journal:  BMC Pharmacol Toxicol       Date:  2013-10-21       Impact factor: 2.483

8.  The impact of national vaccination policy changes on influenza incidence in the Netherlands.

Authors:  Scott A McDonald; Liselotte van Asten; Wim van der Hoek; Gé A Donker; Jacco Wallinga
Journal:  Influenza Other Respir Viruses       Date:  2016-02-02       Impact factor: 4.380

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.